Provectus Biopharmaceuticals, Inc. financial data

Symbol
PVCT on OTC
Industry
Pharmaceutical Preparations
Location
800 S. Gay Street, Suite 1610, Knoxville, TN
State of incorporation
DE
Fiscal year end
December 31
Former names
PROVECTUS PHARMACEUTICALS INC (to 12/18/2013), PROVECTUS PHARMACEUTICAL INC (to 5/15/2002), ZAMAGE DIGITAL IMAGING INC (to 4/1/2002), SPM GROUP INC (to 11/14/2001)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 12.2 % -35.7%
Debt-to-equity -115 % +8.36%
Return On Equity 43.3 % -4.27%
Return On Assets -289 % -62.8%
Operating Margin -387 % +21.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 420M shares +0.18%
Common Stock, Shares, Outstanding 420M shares +0.18%
Entity Public Float 45.5M USD +102%
Common Stock, Value, Issued 420K USD +0.18%
Weighted Average Number of Shares Outstanding, Basic 420M shares +0.09%
Weighted Average Number of Shares Outstanding, Diluted 420M shares +0.09%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 724K USD +20.4%
Research and Development Expense 1.86M USD +12.3%
General and Administrative Expense 1.67M USD -13.4%
Operating Income (Loss) -2.8M USD +5.96%
Nonoperating Income (Expense) -226K USD -18.6%
Net Income (Loss) Attributable to Parent -3.03M USD +4.49%
Earnings Per Share, Basic -0.01 USD/shares 0%
Earnings Per Share, Diluted -0.01 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 187K USD -49%
Assets, Current 760K USD -52.3%
Property, Plant and Equipment, Net 5.33K USD -62.6%
Operating Lease, Right-of-Use Asset 36.7K USD -56.1%
Assets 802K USD -52.5%
Accounts Payable, Current 1.38M USD -22.6%
Employee-related Liabilities, Current 0 USD -100%
Liabilities, Current 6.22M USD -32.1%
Operating Lease, Liability, Noncurrent 12.7K USD -79.4%
Liabilities 6.22M USD -32.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -60.2K USD -66.3%
Retained Earnings (Accumulated Deficit) -255M USD -1.2%
Stockholders' Equity Attributable to Parent -5.42M USD +27.9%
Liabilities and Equity 802K USD -52.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.04M USD -67.4%
Net Cash Provided by (Used in) Financing Activities 781K USD +51.5%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 420M shares +0.18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -264K USD -139%
Deferred Tax Assets, Valuation Allowance 47.3M USD +1.51%
Deferred Tax Assets, Gross 47.4M USD +1.51%
Operating Lease, Liability 37.7K USD -55.6%
Depreciation 2.23K USD +0.05%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.05M USD +3.72%
Lessee, Operating Lease, Liability, to be Paid 38.5K USD -56.7%
Operating Lease, Liability, Current 37.7K USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.7K USD +0%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.8K USD -74.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 790 USD -80.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 25.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 41.9M USD -0.29%
Preferred Stock, Shares Authorized 25M shares 0%
Operating Lease, Payments 11.6K USD +8.36%
Additional Paid in Capital 249M USD +2.11%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%